PARP1 and posterior cortical atrophy: PARP inhibitors are a new class of targeted drugs developed recently, which offer a novel approach to treating PCa by utilizing mutations in germline and somatic DNA damage repair (DDR) pathways, which allows for a genetically stratified treatment strategy [5].